American Red Cross To Participate In Cerus Corporation' IDE Study To Address Chikungunya And Dengue Blood Safety Risks
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) today announced that the American Red Cross will participate in Cerus’ clinical protocol to make the INTERCEPT Blood System for platelets available under an Expanded Access Investigational Device Exemption (IDE) to regions in the United States with outbreaks of chikungunya and dengue virus.
"In Puerto Rico, dengue viruses have been present for decades, but this is the first year that we've also been concerned about the potential risk of transfusion-transmitted chikungunya," said Susan Stramer, vice president, scientific affairs, Biomedical Services, American Red Cross. "With no test available to screen donations for chikungunya infection, investigational pathogen inactivation is a viable alternative for the Red Cross to implement so that platelet collections may resume in Puerto Rico during this epidemic."
Help employers find you! Check out all the jobs and post your resume.
"In Puerto Rico, dengue viruses have been present for decades, but this is the first year that we've also been concerned about the potential risk of transfusion-transmitted chikungunya," said Susan Stramer, vice president, scientific affairs, Biomedical Services, American Red Cross. "With no test available to screen donations for chikungunya infection, investigational pathogen inactivation is a viable alternative for the Red Cross to implement so that platelet collections may resume in Puerto Rico during this epidemic."
Help employers find you! Check out all the jobs and post your resume.